NCT01564758 - Post Marketing Surveillance Study on Linezolid | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

March 31, 2005

Study Completion Date

March 31, 2005

Conditions

Gram-Positive Bacterial Infections

Interventions

DRUG

Linezolid

"1. Vancomycin-resistant, E. faecium, including concurrent bacteremia: Linezolid for 600mg (IV or oral) every 12 hours for 14-28 days~2. Nosocomial infection, cSSTI: Linezolid for 600mg (IV or oral) every 12 hours for 10-14 days~3. Uncomplicated SSTI: Linezolid for 400mg oral every 12 hours for 10-14 days"